Submitted in 2010, with no testing proposals, this substance has not undergone any aspect of the REACH evaluation process to date.

This salt is an analogue with manganese dichloride (MnCl2) which, because of its solubility and bioavailability, is often the test material choice for most academic studies which end up being published in peer-review literature. The outcome of these publications can change the hazard assessment of this dossier via read-across with its analogue MnCl2.  Hence, literature review is carried every two years. Furthermore, new information on two reproductive endpoints (two generation reproductive toxicity and pre-natal developmental toxicity) are available from the International Manganese Institute’s (IMnI) worker safety program. Both studies used MnCl2 as the test material and the information obtained from both studies is read-across to manganese dinitrate. Therefore, the information from the published literature and from those studies initiated by the IMnI triggered a spontaneous dossier update in 2017..

The update considered new uses and new data especially that on reproductive toxicity. This was a foresight, as ECHA's request to update this dossier in January 22, 2018 encourage the review of endpoints associated with reproductive toxicity potential - http://consortium.manganese.org/news/article/four-manganese-substances-short-listed-by-the-echa-as-substances-of-potenti. Upon the review of the December, 2017 version of the submitted dossier, the consortium considered the information in the latest dossier up-to-date.

However, earlier this year (2019)  in alignment with with the information submitted on the other analogue substance, this dossier was updated. All co-registrants that had met their financial obligations were provided with the following:

1) Updated CSR

2) Exposure scenarios for their eSDS

3) Updated CLP classification.

An SDS temeplate has been prepared (Q3, 2019) for industry's use. This can be provided to you upon request - contact reach@manganese.org

Note: Post 2018, the consortium will no longer invoice co-registrants  for ECHA requested studies retrospectively. All compliance check related work will require co-registrants to contribute their share before any dossier update work can begin.